Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-014236
Filing Date
2022-08-03
Accepted
2022-08-03 16:08:16
Documents
62
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fate-20220630.htm   iXBRL 10-Q 3186413
2 EX-10.2 fate-ex10_2.htm EX-10.2 172647
3 EX-31.1 fate-ex31_1.htm EX-31.1 15403
4 EX-31.2 fate-ex31_2.htm EX-31.2 15515
5 EX-32.1 fate-ex32_1.htm EX-32.1 10909
  Complete submission text file 0000950170-22-014236.txt   13137485

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fate-20220630_def.xml EX-101.DEF 275351
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fate-20220630.xsd EX-101.SCH 63635
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fate-20220630_pre.xml EX-101.PRE 405242
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fate-20220630_cal.xml EX-101.CAL 46925
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fate-20220630_lab.xml EX-101.LAB 514781
56 EXTRACTED XBRL INSTANCE DOCUMENT fate-20220630_htm.xml XML 3230100
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 221132613
SIC: 2836 Biological Products, (No Diagnostic Substances)